Morton J D, Harrison L B, Peschel R E
Radiology. 1986 Apr;159(1):249-52. doi: 10.1148/radiology.159.1.3754056.
Of 179 patients with stage B or C adenocarcinoma of the prostate, 106 underwent iodine-125 seed-implant therapy (I-125 SI) and 73 received external-beam radiation therapy (EB). A retrospective analysis determined disease-free survival rate, local tumor control, and complication rate for each treatment group. The 5-year disease-free survival rates for SI-treated patients were 75% for stage B and 30% for stage C groups. Corresponding rates for EB-treated patients were 75% and 40%, respectively. The rate of local tumor control for stage B patients was 85% for SI-treated and 88% for EB-treated patients. The corresponding rates for stage C tumors were 75% for SI-treated and 92% for EB-treated patients. The rate of long-term complications in each group was approximately 10%. For stage B cancer of the prostate, I-125 SI treatment is an acceptable alternative to EB therapy; our data are inconclusive regarding stage C treatment, but EB therapy is preferred.
在179例B期或C期前列腺腺癌患者中，106例接受了碘-125粒子植入治疗（I-125 SI），73例接受了外照射放疗（EB）。一项回顾性分析确定了每个治疗组的无病生存率、局部肿瘤控制率和并发症发生率。接受SI治疗的患者，B期的5年无病生存率为75%，C期为30%。接受EB治疗的患者相应比例分别为75%和40%。B期患者的局部肿瘤控制率，接受SI治疗的为85%，接受EB治疗的为88%。C期肿瘤的相应比例，接受SI治疗的为75%，接受EB治疗的为92%。每组的长期并发症发生率约为10%。对于B期前列腺癌，I-125 SI治疗是EB治疗的一个可接受的替代方案；我们的数据对于C期治疗尚无定论，但EB治疗更受青睐。
